China accepts BRUKINSA sNDA for CLL/SLL with breakthrough therapy; board adds two directors

BeOne Medicines Ltd.

China NMPA accepted sNDA for BRUKINSA (zanubrutinib) in CLL/SLL, supported by Phase 3 SEQUOIA trial (HR=0.42 for PFS vs B+R).
First breakthrough therapy designation for BRUKINSA in China; filing seeks expansion from relapsed/refractory to frontline use.
Director Jing-Shyh (Sam) Su resigned Jan 31, 2022; no disagreement disclosed.
Board expanded to 12; appointed Margaret Dugan, M.D. and Alessandro Riva, M.D. effective Feb 1, 2022.
New directors receive standard cash compensation ($60K/yr) and share options valued at $400K each, pro-rated first year.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jing-Shyh (Sam) Su

Director

ONC · BeOne Medicines Ltd.

Effective: 2022-01-31
Filed: February 2, 2022, 6:59 PM ET

On January 31, 2022, Jing-Shyh (Sam) Su resigned from the Board of Directors (the “Board”) of BeiGene, Ltd. (the “Company”).

Appointed

Alessandro Riva

Director

ONC · BeOne Medicines Ltd.

Effective: 2022-02-01
Filed: February 2, 2022, 6:59 PM ET

On February 1, 2022, the Board enlarged the Board from 11 to 12 members and appointed Margaret Dugan, M.D. and Alessandro Riva, M.D. to fill the two vacancies.

Appointed

Margaret Dugan

Director

ONC · BeOne Medicines Ltd.

Effective: 2022-02-01
Filed: February 2, 2022, 6:59 PM ET

On February 1, 2022, the Board enlarged the Board from 11 to 12 members and appointed Margaret Dugan, M.D. and Alessandro Riva, M.D. to fill the two vacancies.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jing-Shyh (Sam) Su resigned as Director at BeOne Medicines Ltd..

Action: resigned
Role: Director

Exact text from the filing

On January 31, 2022, Jing-Shyh (Sam) Su resigned from the Board of Directors (the “Board”) of BeiGene, Ltd. (the “Company”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Alessandro Riva was appointed as Director at BeOne Medicines Ltd..

Action: appointed
Role: Director

Exact text from the filing

On February 1, 2022, the Board enlarged the Board from 11 to 12 members and appointed Margaret Dugan, M.D. and Alessandro Riva, M.D. to fill the two vacancies.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Margaret Dugan was appointed as Director at BeOne Medicines Ltd..

Action: appointed
Role: Director

Exact text from the filing

On February 1, 2022, the Board enlarged the Board from 11 to 12 members and appointed Margaret Dugan, M.D. and Alessandro Riva, M.D. to fill the two vacancies.

View on SEC.gov

BeOne Medicines Ltd. filing history →

Source: SEC EDGAR

accession 0001651308-22-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.